XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q2)Dec 31, 2024 | (Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -30.29%214M | 214.29%64M | 0.55%1.1B | -39.81%254M | 16.50%593M | 59.90%307M | -80.65%-56M | -19.35%1.09B | 30.25%422M | -15.17%509M |
Net income from continuing operations | 63.68%311M | 148.28%144M | 89.30%354M | 321.88%71M | -40.68%35M | 102.13%190M | -12.12%58M | -75.39%187M | -125.20%-32M | -43.27%59M |
Operating gains losses | 14.29%8M | 175.00%3M | -95.28%6M | -90.00%9M | -175.00%-6M | -74.07%7M | -300.00%-4M | 876.92%127M | -34.31%90M | 142.11%8M |
Depreciation and amortization | -10.00%36M | 10.53%189M | 2.80%734M | 7.87%192M | 80.87%331M | -77.01%40M | -4.47%171M | 3.78%714M | -2.73%178M | 6.40%183M |
Deferred tax | 40.43%66M | 7.69%14M | 183.33%17M | -66.67%-35M | -180.00%-8M | 123.81%47M | 425.00%13M | 104.80%6M | 89.18%-21M | 200.00%10M |
Other non cash items | -769.23%-87M | -72.09%12M | 13.04%130M | 15.15%38M | 227.27%36M | -45.83%13M | -8.51%43M | 19.79%115M | 230.00%33M | -50.00%11M |
Change In working capital | -548.28%-130M | 24.21%-288M | -128.05%-187M | -115.12%-26M | -18.80%190M | 117.79%29M | -16.92%-380M | 11.83%-82M | 112.35%172M | -17.61%234M |
-Change in receivables | -385.71%-140M | 16.41%-107M | 17.81%-120M | -250.00%-135M | -18.26%94M | 119.22%49M | -33.33%-128M | -186.27%-146M | 718.18%90M | -28.13%115M |
-Change in inventory | -52.56%37M | -23.64%-68M | 2,800.00%54M | 24.53%66M | 20.45%-35M | 56.00%78M | 9.84%-55M | 97.70%-2M | 1,160.00%53M | 50.00%-44M |
-Change in payables and accrued expense | 72.45%-27M | 42.64%-113M | -283.33%-121M | 48.28%43M | -19.63%131M | -333.33%-98M | -17.26%-197M | 46.67%66M | -61.33%29M | -23.11%163M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -30.07%214M | 216.36%64M | 0.55%1.1B | -39.81%254M | 16.50%593M | 59.38%306M | -77.42%-55M | -19.35%1.09B | 30.25%422M | -15.17%509M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 316.22%80M | 14.47%-136M | 8.71%-524M | 10.45%-120M | -101.94%-208M | 82.13%-37M | -22.31%-159M | 72.35%-574M | 74.33%-134M | 92.11%-103M |
Capital expenditure reported | -106.67%-62M | 23.39%-95M | 0.60%-496M | 4.03%-143M | -49.62%-199M | 73.45%-30M | -19.23%-124M | 0.00%-499M | 19.02%-149M | -24.30%-133M |
Net PPE purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 516.67%37M | -275.00%-14M | --43M |
Net business purchase and sale | 2,314.29%155M | -17.14%-41M | 41.76%-53M | -106.90%-2M | 30.77%-9M | 92.71%-7M | -218.18%-35M | 94.36%-91M | 108.36%29M | 98.92%-13M |
Net other investing changes | ---- | ---- | 219.05%25M | ---- | ---- | ---- | ---- | -170.00%-21M | --0 | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 316.22%80M | 14.47%-136M | 8.71%-524M | 10.45%-120M | -101.94%-208M | 82.13%-37M | -22.31%-159M | 72.35%-574M | 74.33%-134M | 92.11%-103M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -77.27%-195M | -126.15%-147M | 11.98%-441M | -4.20%-124M | -102.86%-142M | 32.52%-110M | 56.38%-65M | -224.01%-501M | -151.74%-119M | -118.82%-70M |
Net issuance payments of debt | -892.31%-103M | -300.00%-32M | -42.67%-107M | -300.00%-12M | -488.24%-100M | 128.26%13M | 11.11%-8M | -108.80%-75M | -100.84%-3M | -103.40%-17M |
Net common stock issuance | -48.15%-40M | -31.03%-38M | 51.85%-117M | 27.66%-34M | -50.00%-27M | 47.06%-27M | 77.17%-29M | -35.75%-243M | 12.96%-47M | 78.05%-18M |
Cash dividends paid | 0.00%-57M | -25.00%-35M | 1.15%-172M | 1.72%-57M | -11.11%-30M | 1.72%-57M | 9.68%-28M | 0.57%-174M | 4.92%-58M | 3.57%-27M |
Net other financing activities | --5M | ---42M | -400.00%-45M | -90.91%-21M | 287.50%15M | ---- | ---- | 90.43%-9M | 8.33%-11M | 55.56%-8M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -77.27%-195M | -126.15%-147M | 11.98%-441M | -4.20%-124M | -102.86%-142M | 32.52%-110M | 56.38%-65M | -224.01%-501M | -151.74%-119M | -118.82%-70M |
Net cash flow | ||||||||||
Beginning cash position | 16.29%1.78B | 6.93%1.96B | 0.60%1.83B | 17.12%1.94B | 29.82%1.72B | 4.87%1.53B | 0.60%1.83B | -18.52%1.82B | -11.05%1.66B | -39.19%1.33B |
Current changes in cash | -16.15%135M | 21.51%-219M | 682.35%133M | -94.08%10M | -28.27%241M | 190.45%161M | 10.00%-279M | 105.35%17M | 428.13%169M | 200.90%336M |
Effect of exchange rate changes | -297.06%-67M | 248.00%37M | 0.00%-6M | 40.00%7M | -340.00%-22M | -29.17%34M | 53.70%-25M | 93.75%-6M | 106.67%5M | -135.71%-5M |
End cash Position | 7.08%1.85B | 16.29%1.78B | 6.93%1.96B | 6.93%1.96B | 17.12%1.94B | 29.82%1.72B | 4.87%1.53B | 0.60%1.83B | 0.60%1.83B | -11.05%1.66B |
Free cash flow | -44.93%152M | 82.68%-31M | 1.52%602M | -59.34%111M | 4.79%394M | 249.37%276M | -32.59%-179M | -30.64%593M | 92.25%273M | -23.73%376M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |